Valneva SE (NASDAQ:VALN - Get Free Report) shares saw strong trading volume on Friday . 46,675 shares were traded during mid-day trading, an increase of 28% from the previous session's volume of 36,538 shares.The stock last traded at $6.44 and had previously closed at $6.38.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Guggenheim decreased their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th.
Read Our Latest Stock Report on Valneva
Valneva Price Performance
The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm's fifty day simple moving average is $6.77 and its 200-day simple moving average is $5.74. The firm has a market capitalization of $525.23 million, a PE ratio of -48.31 and a beta of 1.85.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. On average, research analysts forecast that Valneva SE will post 0.13 earnings per share for the current fiscal year.
Institutional Trading of Valneva
Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC acquired a new position in Valneva during the 1st quarter valued at about $94,000. ABC Arbitrage SA purchased a new stake in Valneva in the 4th quarter worth $84,000. Finally, Wells Fargo & Company MN grew its stake in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares in the last quarter. Institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
